AdvanSource Biomaterials Corp. (NYSE:ASB) patented a resin that combats MRSA infections.
Methicillin-resistant Staphylococcus aureus is responsible for thousands of hard-to-treat infections every year, but Wakefield, Mass.-based AdvanSource believes that incorporating its new antimicrobial polymer-based resin into medical devices would reduce those numbers.
CEO Michael Adams said "We believe our antimicrobial polymers could now provide medical device developers and manufacturers with a biomaterial choice providing them a competitive advantage in the marketing and sales of medical devices which are constructed or coated with our patented antimicrobial polymers," in a prepared statement.
The technology is drug-free and involves the lacing of an antimicrobial agent into a polymer during its synthesis. The polymer could then be used to mold or coat medical device components, according to AdvanSource, making the devices resistant to MRSA contamination.
The new intellectual property could be big news for the company. Yesterday the New York Stock Exchange warned AdvanSource of a possible delisting unless AdvanSource increases to its profitability and stockholder’s equity.